This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
46
Nicorandil 10 MG Oral Tablet
Tanta university
Tanta, Gharbia Governorate, Egypt
RECRUITINGchange in 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP)
Calculation of 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP) where: Remission: \< 2.6. Low Disease Activity (LDA): ≤ 3.2. Moderate Disease Activity (MDA): 3.2 - 5.1. High Disease Activity (HDA): \> 5.1
Time frame: 3 months
change in Multidimensional Health Assessment Questionnaire (MDHAQ) scores.
Before and 3 months after the intervention, the validated Arabic Multidimensional Health Assessment Questionnaire (MDHAQ) Physical Function: Assessed through 10 activities, scored 0-3 (without difficulty=0, some=1, much=2, unable=3), with higher scores indicating worse function
Time frame: 3 months
The change in the serum level of 8-hydroxydeoxyguanosine (8-OHdG) at baseline and after 3 months.
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
The change in the serum level of Interleukin 6 (IL-6) at baseline and after 3 months .
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
The change in the serum level of C- reactive protein (CRP) at baseline and after 3 months.
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.